A major review of nearly 800,000 men has found prostate cancer screening using a specific test is likely to reduce deaths ...

Prostate-specific antigen (PSA) blood testing likely reduces the risk of death from prostate cancer, found a new review ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

During September’s Prostate Cancer Awareness Month, MidLantic Urology is reminding men of a critical point. It's 0.75. If your PSA increases by 0.75 in 1 year, it could be prostate cancer, and it’s ...

New blood test could show if prostate cancer treatment is failing - The discovery could lead to personalised treatments for ...

Screening for prostate cancer using a blood test likely reduces the risk of dying from prostate cancer and may also reduce the risk of dying from any cause. Screening likely makes little to no ...

Testosterone replacement therapy improved function without PSA recurrence in prostate cancer survivors with hypogonadism.

Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...

“This study adjusted for testosterone levels, which can influence PSA and outcomes, and still found a significant association. This strengthens the argument that PSA response to neoadjuvant therapy is ...

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...